Terrie Curran - Phathom Pharmaceuticals CEO President
| PHAT Stock | USD 6.23 0.03 0.48% |
CEO
Terrie Curran is CEO President of Phathom Pharmaceuticals
| Age | 56 |
| Address | 100 Campus Drive, Florham Park, NJ, United States, 07932 |
| Phone | 877 742 8466 |
| Web | https://www.phathompharma.com |
Latest Insider Transactions
Terrie Curran Latest Insider Activity
Tracking and analyzing the buying and selling activities of Terrie Curran against Phathom Pharmaceuticals stock is an integral part of due diligence when investing in Phathom Pharmaceuticals. Terrie Curran insider activity provides valuable insight into whether Phathom Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Phathom Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Phathom Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Terrie Curran over two weeks ago Disposition of 19109 shares by Terrie Curran of Phathom Pharmaceuticals at 6.5877 subject to Rule 16b-3 | ||
Terrie Curran over a month ago Disposition of 19109 shares by Terrie Curran of Phathom Pharmaceuticals at 6.5877 subject to Rule 16b-3 | ||
Terrie Curran over six months ago Disposition of 33848 shares by Terrie Curran of Phathom Pharmaceuticals at 11.72 subject to Rule 16b-3 |
Phathom Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4378) % which means that it has lost $0.4378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.89) %, meaning that it created substantial loss on money invested by shareholders. Phathom Pharmaceuticals' management efficiency ratios could be used to measure how well Phathom Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.38 in 2025, whereas Return On Tangible Assets are likely to drop (0.93) in 2025. At this time, Phathom Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 573.5 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 267.1 M in 2025.Similar Executives
| Found 9 records | CEO Age | ||
| Maria Palasis | Lyra Therapeutics | 60 | |
| Daniel MBA | Acumen Pharmaceuticals | 55 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Raymond Stevens | Structure Therapeutics American | 61 | |
| JD Esq | Cns Pharmaceuticals | 56 | |
| Kathryn MBA | Blueprint Medicines Corp | 49 | |
| Paula Ragan | X4 Pharmaceuticals | 55 | |
| Jeremy MBA | Day One Biopharmaceuticals | 54 | |
| Nadim Ahmed | Cullinan Oncology LLC | 57 | |
Management Performance
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.44 |
Phathom Pharmaceuticals Leadership Team
Elected by the shareholders, the Phathom Pharmaceuticals' board of directors comprises two types of representatives: Phathom Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phathom. The board's role is to monitor Phathom Pharmaceuticals' management team and ensure that shareholders' interests are well served. Phathom Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phathom Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Guzzo, Chief Officer | ||
| Joseph JD, Chief Officer | ||
| Tom Harris, Chief Officer | ||
| Terrie Curran, CEO President | ||
| Martin Gilligan, Chief Officer | ||
| JD Esq, General Secretary | ||
| David Socks, CoFounder Director | ||
| Aditya Kohli, CoFounder | ||
| Eckhard MD, Chief Officer | ||
| Paul Cocja, Chief Officer | ||
| MPH MD, CoFounder COO |
Phathom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phathom Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.44 | ||||
| Operating Margin | (2.00) % | ||||
| Current Valuation | 336.74 M | ||||
| Shares Outstanding | 69.64 M | ||||
| Shares Owned By Insiders | 3.77 % | ||||
| Shares Owned By Institutions | 97.01 % | ||||
| Number Of Shares Shorted | 14.86 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 7.92 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.